Role of the interval from completion of neoadjuvant therapy to surgery in postoperative morbidity in patients with locally advanced rectal cancer Journal Article
| Authors: | Roxburgh, C. S. D.; Strombom, P.; Lynn, P.; Gonen, M.; Paty, P. B.; Guillem, J. G.; Nash, G. M.; Smith, J. J.; Wei, I.; Pappou, E.; Garcia-Aguilar, J.; Weiser, M. R. |
| Article Title: | Role of the interval from completion of neoadjuvant therapy to surgery in postoperative morbidity in patients with locally advanced rectal cancer |
| Abstract: | Background: Increasing the interval from completion of neoadjuvant therapy to surgery beyond 8 weeks is associated with increased response of rectal cancer to neoadjuvant therapy. However, reports are conflicting on whether extending the time to surgery is associated with increased perioperative morbidity. Methods: Patients who presented with a tumor within 15 cm of the anal verge in 2009–2015 were grouped according to the interval between completion of neoadjuvant therapy and surgery: < 8 weeks, 8–12 weeks, and 12–16 weeks. Results: Among 607 patients, the surgery was performed at < 8 weeks in 317 patients, 8–12 weeks in 229 patients, and 12–16 weeks in 61 patients. Patients who underwent surgery at 8–12 weeks and patients who underwent surgery at < 8 weeks had comparable rates of complications (37% and 44%, respectively). Univariable analysis identified male sex, earlier date of diagnosis, tumor location within 5 cm of the anal verge, open operative approach, abdominoperineal resection, and use of neoadjuvant chemoradiotherapy alone to be associated with higher rates of complications. In multivariable analysis, male sex, tumor location within 5 cm of the anal verge, open operative approach, and neoadjuvant chemoradiotherapy administered alone were independently associated with the presence of a complication. The interval between neoadjuvant therapy and surgery was not an independent predictor of postoperative complications. Conclusions: Delaying surgery beyond 8 weeks from completion of neoadjuvant therapy does not appear to increase surgical morbidity in rectal cancer patients. © 2019, Society of Surgical Oncology. |
| Journal Title: | Annals of Surgical Oncology |
| Volume: | 26 |
| Issue: | 7 |
| ISSN: | 1068-9265 |
| Publisher: | Springer |
| Date Published: | 2019-07-01 |
| Start Page: | 2019 |
| End Page: | 2027 |
| Language: | English |
| DOI: | 10.1245/s10434-019-07340-9 |
| PUBMED: | 30963399 |
| PROVIDER: | scopus |
| PMCID: | PMC6579536 |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work